Potential clinical and economic impact of nonadherence with osteoporosis medications

Calcified Tissue International

Volumn 86, Issue 3, 2010, Pages 202-210

  Hiligsmann, Mickaël ^a   Rabenda, Véronique ^a   Gathon, Henry Jean ^a   Ethgen, Olivier ^a   Reginster, Jean Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Adherence; Burden; Compliance; Cost effectiveness; Osteoporosis; Persistence

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GENERIC DRUG; RISEDRONIC ACID;

AGED; ARTICLE; BONE DENSITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; FEMALE; FRAGILITY FRACTURE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

AGED; BELGIUM; BONE DENSITY CONSERVATION AGENTS; CHRONIC DISEASE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEES, PHARMACEUTICAL; FEMALE; FRACTURES, BONE; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; OSTEOPOROSIS; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 77950863741     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-009-9329-4     Document Type: Article

References (50)

1. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487-497 (Pubitemid 41127293)
2. Hughes DA, Bagust A, Haycox A, Walley T (2001) The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 10:601-615 (Pubitemid 32998372)
3. Cleemput I, Kesteloot K, DeGeest S (2002) A review of the literature on the economics of noncompliance. Room for methodological improvement. Health Policy 59:65-94 (Pubitemid 34098770)
4. Hughes D, Cowell W, Koncz T, Cramer J (2007) Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health 10:498-509 (Pubitemid 350013268)
5. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922-928
6. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811-818
7. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022 (Pubitemid 44175011)
8. Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645-1652 (Pubitemid 44477625)
9. World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1-129
10. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44-47 (Pubitemid 351160875)
11. Cleemput I, van Wilder P, Huybrechts M, Vrijens F (2009) Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 12:441-449
12. Hiligsmann M, Bruyere O, Ethgen O, Gathon HJ, Reginster JY (2008) Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. Bone 43:991-994
13. Reginster JY, Gillet P, Gosset C (2001) Secular increase in the incidence of hip fractures in Belgium between 1984 and 1996: need for a concerted public health strategy. Bull World Health Organ 79:942-946 (Pubitemid 33027173)
14. Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6:1-146
15. Johnell O, Gullberg B, Kanis JA (1997) The hospital burden of vertebral fracture in Europe: a study of national register sources. Osteoporos Int 7:138-144
16. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989-995 (Pubitemid 34105967)
17. Singer BR, McLauchlan GJ, Robinson CM, Christie J (1998) Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 80:243-248 (Pubitemid 128472087)
18. Melton LJ 3rd, Crowson CS, O'Fallon WM (1999) Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9:29-37
19. Institut National de Statistique (2006) Démographie mathématique. Tables de mortalité 2004 et 2002-2004. Direction Générale Statistique et Information Economique, Belgique
20. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8:599-603 (Pubitemid 28566977)
21. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108-112 (Pubitemid 38252423)
22. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468-473 (Pubitemid 39665705)
23. Reginster JY, Gillet P, Ben Sedrine W, Brands G, Ethgen O, de FroidmontC,GossetC(1999) Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics 15:507-514 (Pubitemid 29210953)
24. Autier P, Haentjens P, Bentin J, Baillon JM, Grivegnee AR, Closon MC, Boonen S (2000) Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int 11:373-380 (Pubitemid 30450118)
25. Bouee S, Lafuma A, Fagnani F, Meunier PJ, Reginster JY (2006) Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries. Rheumatol Int 26:1063-1072 (Pubitemid 44450839)
26. Gabriel SE, Tosteson AN, Leibson CL, Crowson CS, Pond GR, Hammond CS, Melton LJ 3rd (2002) Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 13:323-330
27. Melton LJ 3rd, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA (2003) Cost-equivalence of different osteoporotic fractures. Osteoporos Int 14:383-388 (Pubitemid 36919219)
28. Hiligsmann M, Ethgen O, Richy F, Reginster JY (2008) Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 82:288-292
29. Hiligsmann M, Ethgen O, Bruyère O, Richy F, Gathon HJ, Reginster JY (2009) Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12:687-696
30. Hiligsmann M, Bruyere O, Reginster JY (2010) Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int 21:157-165
31. Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27:585-590
32. National Institute for Health and Clinical Excellence (2008) Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Available via DIALOG at:http://www.nice.org.uk/nicemedia/pdf/ TA161guidanceword.pdf. Accessed 15 June 2009
33. Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double- blind, placebo-controlled trial. Ann Intern Med 137:875-883 (Pubitemid 35416623)
34. Stock JL, Bell NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC 2nd (1997) Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 103:291-297
35. Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries- an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047-1061
36. Belgian Centre for Pharmacotherapeutic Information (2009). Available via DIALOG at:http://www.cbip.be/GGR/MPG/MPG-NI.cfm#MP-04090. Accessed 15 June 2009
37. Kanis J, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399-428
38. Lekkerkerker F, Kanis JA, Alsayed N, Bouvenot G, Burlet N, Cahall D, Chines A, Delmas P, Dreiser RL, Ethgen D, Hughes N, Kaufman JM, Korte S, Kreutz G, Laslop A, Mitlak B, Rabenda V, Rizzoli R, Santora A, Schimmer R, Tsouderos Y, Viethel P, Reginster JY (2007) Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 18:1311-1317
39. Briggs A, Sculpher M, Claxton K (2006) Modelling methods for health economic evaluation. Oxford University Press, New York
40. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3-S13
41. Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E (2008) Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 23:1435-1441
42. Cotte FE, Fautrel B, De Pouvourville G (2009) A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis. Med Decis Making 29:125-139
43. Sambrook P (2006) Compliance with treatment in osteoporosis patients-an ongoing problem. Aust Fam Phys 35:135-137
44. InternationalOsteoporosis Foundation (2009)Adherence.Available via DIALOGat:http://www.iofbonehealth.org/health-professionals/about-osteoporosis/ adherence.html. Accessed 15 June 2009
45. Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296-1310
46. Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023-1031
47. Roerholt C, Eiken P, Abrahamsen B (2009) Initiation of antiosteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int 20:299-307
48. Strom O, Borgstrom F, Kanis JA, Jonsson B (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20:23-34
49. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822 (Pubitemid 46698462)
50. Brookhart MA, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Patrick AR, Mogun H, Solmon DH (2007) Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 120:251-256